Silo Pharma Shares Are Trading Lower After the Company Completed a Pre-investigational New Drug Meeting With the FDA for SPOC-15, an Intranasal Prophylactic Treatment for PTST and Stress-induced Anxiety Disorder.
Silo Pharma Shares Are Trading Lower After the Company Completed a Pre-investigational New Drug Meeting With the FDA for SPOC-15, an Intranasal Prophylactic Treatment for PTST and Stress-induced Anxiety Disorder.
Silo Pharma股票交易價格下跌，因公司與FDA完成了針對SPOC-15的預臨床新藥會議，SPOC-15是用於創傷後應激障礙和應激性焦慮障礙的鼻內預防性治療。
Silo Pharma Shares Are Trading Lower After the Company Completed a Pre-investigational New Drug Meeting With the FDA for SPOC-15, an Intranasal Prophylactic Treatment for PTST and Stress-induced Anxiety Disorder.
Silo Pharma的股價走低，此前該公司與美國食品藥品管理局完成了針對PtST和壓力誘發的焦慮症的鼻內預防性治療藥物 SPOC-15 的研究前新藥會議。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間